Chemical apparatus and process disinfecting – deodorizing – preser – Blood treating device for transfusible blood
Patent
1995-03-10
1998-02-24
Warden, Robert J.
Chemical apparatus and process disinfecting, deodorizing, preser
Blood treating device for transfusible blood
4351736, 4352852, 604 4, 935 85, C12N 1587
Patent
active
057209219
ABSTRACT:
The present invention relates to a method and apparatus for the encapsulation of biologically-active substances in red blood cells, characterized by an optionally automated, continuous-flow, self-contained electroporation system which allows withdrawal of blood from a patient, separation of red blood cells, encapsulation of a biologically-active substances in the cells, and optional recombination of blood plasma and the modified red blood cells thereby producing blood with modified biological characteristics. The present invention is particularly suited for use to encapsulate allosteric effectors of hemoglobin, thereby reducing the affinity of erythrocytes for oxygen and improving the release of oxygen from erythrocytes in tissues.
REFERENCES:
patent: 2955076 (1960-10-01), Gossling
patent: 4075076 (1978-02-01), Xylander
patent: 4081340 (1978-03-01), Zimmerman et al.
patent: 4192869 (1980-03-01), Nicolau
patent: 4321259 (1982-03-01), Nicolau
patent: 4473563 (1984-09-01), Nicolau
patent: 4478824 (1984-10-01), Franco et al.
patent: 4622302 (1986-11-01), Sowers
patent: 4652449 (1987-03-01), Ropars
patent: 4695547 (1987-09-01), Hilliard et al.
patent: 4699881 (1987-10-01), Matschke
patent: 4752586 (1988-06-01), Ropars et al.
patent: 4764473 (1988-08-01), Matschke et al.
patent: 4784737 (1988-11-01), Ray et al.
patent: 4800163 (1989-01-01), Hibi et al.
patent: 4804450 (1989-02-01), Mochizuki et al.
patent: 4822470 (1989-04-01), Chang
patent: 4849089 (1989-07-01), Marshall, III
patent: 4849355 (1989-07-01), Wong
patent: 4874690 (1989-10-01), Goodrich et al.
patent: 4882281 (1989-11-01), Hilliard et al.
patent: 4906576 (1990-03-01), Marshall, III
patent: 4910140 (1990-03-01), Dower
patent: 4923814 (1990-05-01), Marshall, III
patent: 4931276 (1990-06-01), Franco et al.
patent: 4945050 (1990-07-01), Sanford
patent: 4946793 (1990-08-01), Marshall, III
patent: 4956288 (1990-09-01), Barsoum
patent: 4970154 (1990-11-01), Chang
patent: 5036006 (1991-07-01), Sanford
patent: 5043261 (1991-08-01), Goodrich et al.
patent: 5098843 (1992-03-01), Calvin
patent: 5100627 (1992-03-01), Buican et al.
patent: 5100792 (1992-03-01), Sanford
patent: 5114681 (1992-05-01), Bertoncini et al.
patent: 5124259 (1992-06-01), Tada
patent: 5128257 (1992-07-01), Baer
patent: 5135667 (1992-08-01), Schoendorfer
patent: 5137817 (1992-08-01), Busta et al.
patent: 5139684 (1992-08-01), Kaali et al.
patent: 5232856 (1993-08-01), Firth
patent: 5424209 (1995-06-01), Kearney
Gersonde, et al., Enhancement of the O.sub.2 Release Capacity and of the Bohr-Effect of Human Red Blood Cells after Incorporation of Inositol Hexaphosphate by Fusion with Effector-Containing Lipid Vesicles, Hemoglobin and Oxygen Binding II Origins of Cooperative Binding By Hemoglobins, pp. 277-282 (1982).
Gersonde, et al., Improvement of the Red Blood Cell 0.sub.2 Release Capacity by Lipid Vesicle-mediated Incorporation of Inositol Hexaphosphate, BLUT, vol. 39 pp. 1-7, (1979).
Gersonde, et al., Modification of the Oxygen Affinity of Intracellular Haemoglobin by Incorporation of Polyphosphates into Intact Red Blood Cells and Enhanced O.sub.2 Release in the Capillary System, Biblithca. Haematol., vol. 46, pp. 81-92, (1980).
Gersonde, et al., The Influence of Infusion Rate on the Acute Intravenous Toxicity of Phytic Acid, A Calcium-Binding Agent, Toxicology, vol. 22, pp. 279-286, (1982).
Lehninger, Albert L., Principles of Biochemistry, pp. 181-194, 705-711, 779 (1982).
Mouneimne, et al., Stable Rightward Shifts of the Oxyhemoglobin Dissocation Curve Induced by Encapsulation of Inositol Hexaphosphate in Red Blood Cells Using Electroporation, FEBS Letters, vol. 275, pp. 117-120 (1990).
Nicolau, et al., Incorporation of Allosteric Effectors of Hemoglobin in Red Blood Cells. Biochemical and Physiological Effects. Oxygen Transport in Red Blood Cells. Proceedings of the 12th Aharon Katzir Katchalsky Conference, pp. 141-147 (1984); Biblthca Heamat., No. 51, pp. 92-107 (Karger, Basel 1985).
Nicolau, et al., Short and Long Term Physiological Effects of Improved Oxygen Transport by Red Blood Cells Containing Inositol Hexaphosphate, Phytic Acid: Chemistry and Applications, pp. 265-290 (1986).
Ropars, et al., Improved Oxygen Delivery to Tissues and Iron Chelator Transport through the Use of Lysed and Resealed Red Blood Cells: A New Perspective on Cooley's Anemia Therapy, Annals New York Acad. of Sci., vol. 445, pp. 304-315, 477-491 (1985).
Teisseire, et al., Long-Term Physiological Effects of Enhanced O.sub.2 Release by Inositol Hexaphosphate-loaded Erythrocytes, Proc. Natl. Acad. Sci. USA, vol. 84, pp. 6894-6898 (1987).
Teisseire, et al., Physiological Effects on High-P.sub.50 Erythrocyte Transfusion on Piglets, J. Appl. Physiol., vol. 58, pp. 1810-1817 (1985).
Weiner, Murray, Right Shifting of Hb-O.sub.2 Dissociation in Viable Red Blood Cells by Liposomal Technique, Biology of the Cell, vol. 47, pp. 65-70 (1983).
Dawson E. Leigh
Entremed, Inc.
Warden Robert J.
LandOfFree
Flow electroporation chamber and method does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Flow electroporation chamber and method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Flow electroporation chamber and method will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1873359